Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases

Annalina Avram; Cátia Duarte; Maria José Santos; Charalampos Papagoras; Konstantinos Ritis; Roberto Scarpioni; Wolfgang A Schmidt; Panagiotis Skendros

doi:10.1016/S1297-319X(15)30004-X

Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases

Joint Bone Spine. 2015 Oct:82 Suppl 1:eS17-29. doi: 10.1016/S1297-319X(15)30004-X.

Authors

Annalina Avram¹, Cátia Duarte², Maria José Santos³, Charalampos Papagoras⁴, Konstantinos Ritis⁵, Roberto Scarpioni⁶, Wolfgang A Schmidt⁷, Panagiotis Skendros⁸

Affiliations

¹ Medical Doctor; Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin - Buch, Berlin, Germany.
² Rheumatologist, Rheumatology Department, Centro Hospitalar, Universitario de Coimbra, Coimbra, Portugal.
³ Medical Doctor, Department of Rheumatology, Hospital Garcia de 'Orta, Lisbon, Portugal; University Hospital of Alexandroupolis, Alexandroupolis, Greece.
⁴ Rheumatologist, First Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
⁵ Professor of Internal Medicine, First Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
⁶ Head, Department of Nephrology and Dialysis, Ospedale AUSL "Guglielmo da Saliceto", Piacenza, Italy.
⁷ Deputy Director, Immanuel Krankenhause Berline Medical Centre for Rheumatology Berlin - Buch, Berlin, Germany. Electronic address: [email protected].
⁸ Assistant Professor of Internal Medicine, First Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.

PMID: 26717798
DOI: 10.1016/S1297-319X(15)30004-X

Abstract

A subgroup of patients with gouty arthritis have a chronic recurring form that is particularly difficult to treat. Such patients experience repeated flares and often have abundant tophi. Many also have underlying comorbidities, such as renal impairment, cardiovascular disease, gastrointestinal disorders, obesity, and hypertension, which contraindicate the use of standard anti-inflammatory medications. Five patients with difficult to treat gouty arthritis who were either candidates and/or treated with anti-IL therapy are described.

Keywords: Anakinra; Anti-IL-1β therapy; Canakinumab; Gouty arthritis; Tophaceous gout.

Publication types

Case Reports

MeSH terms

Aged
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Arthritis, Gouty / drug therapy*
Chronic Disease
Colchicine / therapeutic use
Comorbidity
Febuxostat / therapeutic use
Gout Suppressants / therapeutic use*
Humans
Interleukin 1 Receptor Antagonist Protein / therapeutic use
Interleukin-1 / antagonists & inhibitors*
Male
Patient Selection*
Prednisolone / therapeutic use
Recurrence

Substances

Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Gout Suppressants
Interleukin 1 Receptor Antagonist Protein
Interleukin-1
Febuxostat
canakinumab
Prednisolone
Colchicine